The themes Vanda Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
基于 Vanda Pharmaceuticals Inc. 自己向美国证券交易委员会(SEC)提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
US$4.00+1.3%11月13日 收盘
数据截至2026年9月30日,来自2026年10月29日提交的10-Q
公司指引:2026 财年营收 约 US$240M — 同比增长 11.1%,低于刚公布的 24.1%
Just reported
From Vanda Pharmaceuticals's results release of 2026年10月28日; its quarterly report has since been filed.
Actual
US$69.8M
+24% y/y
+38% q/q
Guided
—
No guide given
Actual
-US$0.37
Guided
—
No guide given
Actual
-US$23.5M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade F-
价格下方的色带显示每个日期的评级,仅依据当时已公开的文件计算。
显示 Vanda Pharmaceuticals Inc. 评级历史 41 个季度中的 2 个。 其余 39 个可回溯到 2016年11月。